Apoptosis inducer43 is an agent that promotes apoptosis. It has the capability to induce apoptosis in HCT116 cells, cause cell cycle arrest at the SubG0-G1 phase, trigger secondary necrosis, and increase the expression of caspase-3, p53, and Bax/Bcl-2. This compound also inhibits tumor growth in solid Ehrlich carcinoma (SEC) mouse models. Apoptosis inducer43 is applicable for research in colon cancer, leukemia, non-small cell lung cancer, and other cancers.

Apoptosis inducer 43 (Compound 5f) at a concentration of 10 μM demonstrates anticancer activity, achieving an average inhibition rate of over 80% in NCI 60 cell lines, which include leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, and breast cancer, with an average GI₅₀ below 5 μM. Additionally, when used at 1.79-10 μM for 24 hours, it induces cell cycle arrest in the HCT-116 cells, primarily at the SubG0/G1 phase, and triggers apoptosis.

Compound 5f, known as Apoptosis inducer 43, administered intraperitoneally at 10 mg/kg three times a week for 14 days, demonstrated antitumor activity in a solid Ehrlich carcinoma (SEC) mouse model.